Oral arguments today in a federal appeals court case brought by the AHA, Association of American Medical Colleges, America’s Essential Hospitals and three hospital organizations to challenge a nearly 30% reduction to Medicare payments for 340B drugs focused on procedure issues. However, as evidenced by questions from the judges, the court seemed most interested in whether the Medicare statute expressly precludes judicial review of the Department of Health and Human Services’ actions. The attorney representing the government argued that the Congress clearly intended to preclude review, arguing that the specific section relied on to make the payment reduction was “mushed up together” in the section of the law that authorized preclusion. The attorney for the AHA and other plaintiffs argued forcefully that evidence of preclusion must be clear and convincing and that the preclusion provision identifies only specific statutory sections that are shielded from review, including sections added to law after the addition of the section at issue in the case. There also was discussion of whether plaintiffs had adequately presented their claims to the Centers for Medicare & Medicaid Services and whether CMS had the legal authority to reduce reimbursement to section 340B hospitals by almost 30% under the section of the statute establishing the reimbursement methodology for separately payable outpatient prospective payment system drugs. The AHA hopes for a ruling from the court sometime this summer. To listen to a recording of today’s oral arguments, click here
 

Headline
The Washington Post yesterday published a letter to the editor from AHA President and CEO Rick Pollack responding to an April 18 editorial criticizing the 340B…
Headline
The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program because “a rebate mechanism of any kind…
Headline
The AHA and others April 17 filed an amicus brief requesting the U.S. Court of Appeals for the 4th Circuit grant en banc review of a panel decision that…
Headline
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…
Headline
The U.S. District Court for the District of Columbia March 31 vacated a Health Resources and Services Administration policy instituted in 2013 that restricted…
Headline
The U.S. Court of Appeals for the 4th Circuit March 31 upheld a preliminary injunction issued by the U.S. District Court for the District of West Virginia…